Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 9/20 | 0.52 |
| ▸ | EPAS1 | Q99814 | 8/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.45 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4475222 | 0.90 | MEN1 (0.51) | HIF1AEPAS1NPC1RAB9AHPGD | |
| SCHEMBL4471596 | 0.81 | HPGD (0.50) | HIF1AEPAS1HPGDCA1CA2 | |
| SCHEMBL2825117 | 0.81 | HIF1A (0.52) | HIF1AEPAS1HPGDALDH1A1 | |
| SCHEMBL27666053 | 0.77 | HIF1A (0.54) | HIF1AEPAS1HPGDALDH1A1 | |
| SCHEMBL2561679 | 0.75 | HIF1A (0.68) | HIF1AEPAS1 | |
| SCHEMBL14178660 | 0.75 | HIF1A (0.63) | HIF1AEPAS1 | |
| SCHEMBL4481432 | 0.73 | ALDH1A1 (0.56) | HPGDALDH1A1LMNAL3MBTL1 | |
| SCHEMBL14930293 | 0.73 | HIF1A (0.61) | HIF1AEPAS1 | |
| SCHEMBL4466275 | 0.73 | RAB9A (0.47) | NPC1RAB9AHPGDCA1CA2 | |
| SCHEMBL2832072 | 0.72 | HIF1A (0.49) | HIF1AEPAS1HPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100532375-C | Amidomethyl-substituted 2-(4-sulfonylamino)-3-hydroxy-3,4-dihydro-2h-chromen-6-yl compounds, a process and intermediates for their production, and pharmaceutical containing the compound | SOLVAY PHARM GMBH (DE) | 2009-08-26 | — | — | CN | disclosed |
| US-7534903-B2 | Use of amidomethyl-substituted 2-(4-sulfonylamino)-3-hydroxy-3,4-dihydro-2H-chromen-6-yl-compounds in the treatment of cardiac arrhythmia and other disease states | SOLVAY PHARMACEUTICALS GMBH (DE) | 2009-05-19 | — | — | US | disclosed |
| EP-1678130-B1 | AMIDOMETHYL-SUBSTITUTED 2-(4-SULFONILAMINO)-3-HIDROXY-3,4-DIHYDRO-2H-CHROMIUM-6-YL-DERIVATIVES AND DRUGS CONTAINING SAID COMPOUNDS | SOLVAY PHARM GMBH (DE) | 2008-08-20 | — | — | EP | disclosed |
| US-20080113999-A1 | Use of Amidomethyl-Substituted 2-(4-Sulfonylamino)-3-Hydroxy-3,4-Dihydro-2H-Chromen-6-yl-Compounds in the Treatment of Cardiac Arrhythmia and Other Disease States | SOLVAY PHARMACEUTICALS GMBH (DE) | 2008-05-15 | — | — | US | disclosed |
| US-7368582-B2 | Amidomethyl-substituted 2-(4-sulfonylamino)-3-hydroxy-3,4-dihydro-2H-chromen-6-yl compounds, a process and intermediates for their production, and pharmaceutical compositions containing them | SOLVAY PHARMACEUTICALS GMBH (DE) | 2008-05-06 | — | — | US | disclosed |
| CN-1894233-A | Amidomethyl-substituted 2-(4-sulfonylamino)-3-hydroxy-3,4-dihydro-2h-chromen-6-yl compounds, a process and intermediates for their production, and pharmaceutical compositions containing them | SOLVAY PHARM GMBH (DE) | 2007-01-10 | — | — | CN | disclosed |
| US-20050148659-A1 | Amidomethyl-substituted 2-(4-sulfonylamino)-3-hydroxy-3,4-dihydro-2H-chromen-6-yl compounds, a process and intermediates for their production, and pharmaceutical compositions containing them | SOLVAY PHARMACEUTICALS GMBH (DE) | 2005-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148659-A1 | Amidomethyl-substituted 2-(4-sulfonylamino)-3-hydroxy-3,4-dihydro-2H-chromen-6-yl compounds, a process and intermediates for their production, and pharmaceutical compositions containing them | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP4B1, CYP3A4 | HIF1A 2727/4885EPAS1 2767/4885NPC1 1231/4885 |
| US-20080113999-A1 | Use of Amidomethyl-Substituted 2-(4-Sulfonylamino)-3-Hydroxy-3,4-Dihydro-2H-Chromen-6-yl-Compounds in the Treatment of Cardiac Arrhythmia and Other Disease States | KCNH1, RYR2, KCNJ2 | HIF1A 2348/4885EPAS1 3295/4885NPC1 1972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.